Table 3.
Univariable and multivariable Cox proportional hazard regression analyses of PFS
| Factor | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
|
|
|
|||
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex | ||||
| Male | Reference | Reference | ||
| Female | 1.818 (0.874-3.783) | 0.110 | 0.719 (0.323-1.601) | 0.419 |
| Age (years) | ||||
| ≤60 | Reference | |||
| >60 | 1.201 (0.591-2.440) | 0.613 | ||
| ECOG performance status | ||||
| 0-1 | Reference | Reference | ||
| 2 | 1.983 (0.983-4.001) | 0.056 | 1.399 (0.598-3.271) | 0.438 |
| Previous lines of therapies for recurrent or metastatic disease | ||||
| ≤2 | Reference | Reference | ||
| >2 | 1.703 (0.842-3.442) | 0.138 | 1.459 (0.640-3.328) | 0.369 |
| Previous therapeutic regimen | ||||
| Excluding taxanes | Reference | Reference | ||
| Including taxanes | 0.554 (0.253-1.215) | 0.140 | 0.658 (0.276-1.569) | 0.345 |
| Metastatic sites | ||||
| ≤2 | Reference | |||
| >2 | 0.977 (0.477-2.003) | 0.950 | ||
| Pathological type | ||||
| Adenocarcinoma | Reference | |||
| Squamous cell carcinoma | 0.807 (0.307-2.122) | 0.664 | ||
| Sarcoma | 1.126 (0.265-4.789) | 0.872 | ||
| Urothelial carcinoma | 0.983 (0.132-7.331) | 0.986 | ||
| Tumor entities | ||||
| Breast cancer | Reference | |||
| Gynecological cancers | 1.351 (0.543-3.361) | 0.517 | ||
| Gastrointestinal cancers | 2.124 (0.77-5.858) | 0.146 | ||
| Lung cancer | 2.901 (0.906-9.282) | 0.073 | ||
| Other solid tumors | 1.808 (0.571-5.719) | 0.314 | ||
HR, hazard ratio; ECOG, Eastern Cooperative Oncology Group.